Clinical Trial

Atamparib in Patients With Advanced Solid Tumors

Study acronym: PARP7
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) adenocarcinoma. The study comprises dose escalation (phase Ib) and expansion (phase II).
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-30
Trial Details
NCT Number NCT07374419
Lead Sponsor Nerviano Medical Sciences (Shanghai) Ltd.
Conditions NSCLC Adenocarcinoma, Solid Tumor
Enrollment 178 participants
Start Date 2026-03-18
Primary Completion 2028-07-31 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-29